Diligence memo · auto-generated · as of July 2, 2026

EXSULIN Corp

EXSULIN Corp looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

EXSULIN Corp operates in Biotechnology, based in BURNSVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

EXSULIN Corp has raised $1.0M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $350K on 2012-05-21.

Most recent recorded round closed around 2013-07-29.

Valuation (modeled)modeled

Provath models EXSULIN Corp at approximately $8.5M (range $82K–$96M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.54× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 12.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).

Modeled value ranks above 16% of those peers.

Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.